We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
Read MoreHide Full Article
Key Takeaways
ADMA Biologics boosted gross margin to 57.4% in 2025, driven by yield-enhanced production gains.
ADMA expects 2026 margin expansion from a higher-margin IVIG mix and full-year production benefits.
ADMA secured plasma supply via deals and divestiture, supporting capacity growth through the late 2030s.
ADMA Biologics (ADMA - Free Report) markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
Gross margin improved to 57.4% in 2025 from 51.5% in 2024. Yield-enhanced production transitioned into steady commercial execution in 2025, supported by ongoing FDA lot releases.
ADMA is positioned to benefit in fiscal 2026 from a continued shift in product mix toward higher-margin IVIG therapies, supporting further gross margin expansion. This improvement is expected to be driven by the first full year of yield-enhanced production, reinforcing the company’s operating leverage and supporting its profitability trajectory.
In December 2025, ADMA agreed to divest three plasma centers for $12 million while retaining seven collection facilities. The company secured long-term supply agreements with the buyer, preserving a diversified base of high-titer plasma sources, and has remained on track to complete the transaction in the first quarter of 2026.
Third-party suppliers outperformed expectations in 2025, and newly signed contracts now provide access to more than 280 plasma collection centers — positioning the company to meaningfully enhance ASCENIV’s long-term supply.
Taken together, these initiatives are expected to create a more flexible and capital-efficient supply model, drive accretive cost savings starting in 2026, expand overall production capacity, and support a durable supply outlook through the late 2030s and beyond.
ADMA’s emphasis on disciplined field execution, expanded medical education, and newly launched direct-to-patient initiatives is expected to drive stronger demand utilization while keeping costs in check. This balanced approach should support continued operating leverage and sustained margin expansion through 2026 and beyond.
Competition in the Plasma Therapy Market
ADMA Biologics competes with Grifols (GRFS - Free Report) and Takeda (TAK - Free Report) for plasma-derived products.
GRFS is a leading producer of plasma derivatives globally, ranking among the three largest producers in the industry in terms of total sales, alongside Takeda and CSL Group. The main plasma products that Grifols manufactures are IG, Factor VIII, Alpha 1 (A1PI) and albumin. Grifols also manufactures intramuscular (hyperimmune) immunoglobulins (IGs), ATIII, Factor IX and plasma thromboplastin component.
GRFS has a strong presence in various segments of the plasma derivatives industry, including A1PI, IG and albumin, aided by its dominant position in plasma collection centers and fractionation capacity.
Takeda’s broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard Liquid ECR. The company is developing next-generation IG products with 20% facilitated SCIG (TAK-881). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further.
ADMA’s Price Performance, Valuation & Estimates
Shares of ADMA have lost 31.7% in the past six months against the industry’s gain of 9.6%.
Image Source: Zacks Investment Research
From a valuation perspective, ADMA is expensive at this moment. Going by the price/sales ratio, ADMA’s shares currently trade at 3.49x forward sales, lower than its mean of 3.69x but higher than the industry’s mean of 2.07x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ADMA’s 2026 earnings per share has moved north to 96 cents in the past 60 days, while that for 2027 has remained stable at $1.38.
View the Zacks #1 Rank List
Image: Bigstock
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
Key Takeaways
ADMA Biologics (ADMA - Free Report) markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
Gross margin improved to 57.4% in 2025 from 51.5% in 2024. Yield-enhanced production transitioned into steady commercial execution in 2025, supported by ongoing FDA lot releases.
ADMA is positioned to benefit in fiscal 2026 from a continued shift in product mix toward higher-margin IVIG therapies, supporting further gross margin expansion. This improvement is expected to be driven by the first full year of yield-enhanced production, reinforcing the company’s operating leverage and supporting its profitability trajectory.
In December 2025, ADMA agreed to divest three plasma centers for $12 million while retaining seven collection facilities. The company secured long-term supply agreements with the buyer, preserving a diversified base of high-titer plasma sources, and has remained on track to complete the transaction in the first quarter of 2026.
Third-party suppliers outperformed expectations in 2025, and newly signed contracts now provide access to more than 280 plasma collection centers — positioning the company to meaningfully enhance ASCENIV’s long-term supply.
Taken together, these initiatives are expected to create a more flexible and capital-efficient supply model, drive accretive cost savings starting in 2026, expand overall production capacity, and support a durable supply outlook through the late 2030s and beyond.
ADMA’s emphasis on disciplined field execution, expanded medical education, and newly launched direct-to-patient initiatives is expected to drive stronger demand utilization while keeping costs in check. This balanced approach should support continued operating leverage and sustained margin expansion through 2026 and beyond.
Competition in the Plasma Therapy Market
ADMA Biologics competes with Grifols (GRFS - Free Report) and Takeda (TAK - Free Report) for plasma-derived products.
GRFS is a leading producer of plasma derivatives globally, ranking among the three largest producers in the industry in terms of total sales, alongside Takeda and CSL Group. The main plasma products that Grifols manufactures are IG, Factor VIII, Alpha 1 (A1PI) and albumin. Grifols also manufactures intramuscular (hyperimmune) immunoglobulins (IGs), ATIII, Factor IX and plasma thromboplastin component.
GRFS has a strong presence in various segments of the plasma derivatives industry, including A1PI, IG and albumin, aided by its dominant position in plasma collection centers and fractionation capacity.
Takeda’s broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard Liquid ECR. The company is developing next-generation IG products with 20% facilitated SCIG (TAK-881). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further.
ADMA’s Price Performance, Valuation & Estimates
Shares of ADMA have lost 31.7% in the past six months against the industry’s gain of 9.6%.
Image Source: Zacks Investment Research
From a valuation perspective, ADMA is expensive at this moment. Going by the price/sales ratio, ADMA’s shares currently trade at 3.49x forward sales, lower than its mean of 3.69x but higher than the industry’s mean of 2.07x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ADMA’s 2026 earnings per share has moved north to 96 cents in the past 60 days, while that for 2027 has remained stable at $1.38.
Image Source: Zacks Investment Research
ADMA currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.